IPO registrations (S-1, F-1) · Registrants
Immunovant, Inc.
- SEC CIK
- 1764013 · filings on EDGAR ↗
- Former names
- Health Sciences Acquisitions Corp (2019–2019)
- Registration
- Form S-1, first filed 2019-04-16, last 2020-08-31; 4 initial registrations, 5 amendments
- Outcome
- Final prospectus filed 2019-05-10; declared effective 2019-05-09
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 1000 PARK FORTY PLAZA, Durham, NC 27713
- EIN
- 83-2771572
- Ticker
- IMVT (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Immunovant, Inc. on the corporate pages
Offering terms
- Final price
- $11.50 per share (424B4 filed 2019-05-10, an initial public offering)
- Shares sold
- 10,000,000
- Gross proceeds
- $115,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol HSAC
- Lead underwriters
- Chardan (7,000,000 shares)
- Syndicate
- Morgan Stanley; UBS (3,000,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Immunovant, Inc. EXACT (CIK (EXACT))
- SEC filer: Health Sciences Acquisitions Corp EXACT (CIK (EXACT))
- Person page: Pedro P Granadillo Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Stephanie A Sirota Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 19
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-04-16 | S-1 | S-1 (registration) | Health Sciences Acquisitions Corp | 0001615774-19-005792 ↗ |
| 2019-04-29 | S-1/A | S-1/A (amendment) | Health Sciences Acquisitions Corp | 0001615774-19-006497 ↗ |
| 2019-05-03 | S-1/A | S-1/A (amendment) | Health Sciences Acquisitions Corp | 0001615774-19-007057 ↗ |
| 2019-05-09 | EFFECT | EFFECT (declared effective) | Health Sciences Acquisitions Corp | 9999999995-19-001071 ↗ |
| 2019-05-10 | 424B4 | 424B4 (final prospectus) | Health Sciences Acquisitions Corp | 0001615774-19-007495 ↗ |
| 2020-01-17 | S-1 | S-1 (registration) | Immunovant, Inc. | 0001193125-20-010195 ↗ |
| 2020-02-28 | S-1/A | S-1/A (amendment) | Immunovant, Inc. | 0001193125-20-056986 ↗ |
| 2020-04-03 | S-1/A | S-1/A (amendment) | Immunovant, Inc. | 0001193125-20-096678 ↗ |
| 2020-04-08 | S-1/A | S-1/A (amendment) | Immunovant, Inc. | 0001193125-20-100937 ↗ |
| 2020-04-09 | EFFECT | EFFECT (declared effective) | Immunovant, Inc. | 9999999995-20-000718 ↗ |
| 2020-04-10 | S-1 | S-1 (registration) | Immunovant, Inc. | 0001193125-20-103101 ↗ |
| 2020-04-14 | S-1MEF | S-1MEF (added securities) | Immunovant, Inc. | 0001193125-20-105937 ↗ |
| 2020-04-14 | 424B4 | 424B4 (final prospectus) | Immunovant, Inc. | 0001193125-20-107237 ↗ |
| 2020-04-14 | EFFECT | EFFECT (declared effective) | Immunovant, Inc. | 9999999995-20-000752 ↗ |
| 2020-08-31 | S-1 | S-1 (registration) | Immunovant, Inc. | 0001193125-20-235301 ↗ |
| 2020-09-01 | S-1MEF | S-1MEF (added securities) | Immunovant, Inc. | 0001193125-20-237429 ↗ |
| 2020-09-01 | EFFECT | EFFECT (declared effective) | Immunovant, Inc. | 9999999995-20-002339 ↗ |
| 2020-09-03 | 424B4 | 424B4 (final prospectus) | Immunovant, Inc. | 0001193125-20-238296 ↗ |
| 2021-01-14 | EFFECT | EFFECT (declared effective) | Immunovant, Inc. | 9999999995-21-000163 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-05-03 | S-1/A | registration statement | $11.50 | 10,000,000 | $115,000,000 | Nasdaq HSAC | 3 | primary document; price sentence, shares headline, proceeds computed, cover names 3 | document ↗ | |
| 2019-05-10 | 424B4 | final prospectus | $11.50 | 10,000,000 | $115,000,000 | Nasdaq HSAC | 3 | primary document; price sentence, shares headline, proceeds computed, underwriting table 2, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| GRANADILLO PEDRO P | Director | 1 | 2019 | person page Fuzzy | |
| Health Sciences Holdings, LLC | TenPercentOwner | 3 | 2019 | ||
| Lee Alice | Officer | VPO, Secretary and Treasurer | 1 | 2019 | |
| Makker Gotham | Director | 1 | 2019 | ||
| MIGAUSKY GEORGE V | Director | 10 | 2019–2025 | ||
| Nagendran Sukumar | Director | 1 | 2019 | ||
| SCHOENEBAUM MARK | Director | 1 | 2019 | ||
| Sirota Stephanie A | Officer | VP of CSC | 1 | 2019 | person page Fuzzy |
| WONG RODERICK | Director,Officer | Chief Executive Officer; President and CEO | 13 | 2019 | |
| Yalamanchi Naveen | Director,Officer | Vice President and CFO | 1 | 2019 | |
| Butchko Julia G. | Officer | Chief Development Officer; Chief Dev. & Tech. Officer | 33 | 2019–2024 | |
| Fromkin Andrew J. | Director | 15 | 2019–2026 | ||
| Hughes Douglas J. | Director | 13 | 2019–2026 | ||
| MIDDLEKAUFF W BRADFORD | Officer | General Counsel | 3 | 2019–2020 | |
| Pande Atul | Director | 19 | 2019–2026 | ||
| POTTER MYRTLE S | Director | 2 | 2019 | ||
| Roivant Sciences Ltd. | Director,TenPercentOwner; TenPercentOwner | 11 | 2019–2025 | ||
| Salzmann Peter | Director,Officer | Chief Executive Officer | 43 | 2019–2025 | |
| Torti Frank | Director | 11 | 2019–2026 | ||
| Yanchik Connealy Pamela | Officer | Chief Financial Officer | 4 | 2019–2021 | |
| Zeldin Robert K | Officer | Chief Medical Officer | 2 | 2019 | |
| Venker Eric | Director; Director,Officer | Chief Executive Officer | 5 | 2020–2026 | |
| Elliott Michael James | Officer | Chief Scientific Officer | 3 | 2020–2021 | |
| Jain Rita | Officer | Chief Medical Officer | 4 | 2021 | |
| Macias William L. | Officer | Chief Medical Officer | 28 | 2021–2025 | |
| Barnett Eva Renee | Officer | Chief Financial Officer | 31 | 2021–2025 | |
| Levine Mark S. | Officer | Chief Legal Officer | 22 | 2022–2024 | |
| Stout Jay S | Officer | Chief Technology Officer | 22 | 2023–2026 | |
| Geffner Michael | Officer | Chief Medical Officer; Chief Medical Officer* | 14 | 2024–2025 | |
| Gloria Melanie | Officer | Chief Operating Officer | 11 | 2024–2026 | |
| Van Tuyl Christopher | Officer | Chief Legal Officer | 11 | 2024–2026 | |
| Bauer Jake | Director | 3 | 2025–2026 | ||
| Girao Tiago | Officer | Chief Financial Officer | 6 | 2025–2026 | |
| Susman Robert Graham | Director | 4 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-01-21 | Immunovant, Inc. | Pharmaceuticals | $450,000,000 | $450,000,000 | 11 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Immunovant, Inc. | NY | Form D private offerings | CIK (EXACT) |
| SEC filer | Immunovant, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Pedro P Granadillo | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Stephanie A Sirota | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NC first:
- ALDAGEN INC NC
- FENNEC PHARMACEUTICALS INC. NC
- TENGION INC NC
- Chelsea Therapeutics International, Ltd. NC
- AERIE PHARMACEUTICALS INC NC
- PRECISION BIOSCIENCES INC NC
- Axium Pharmaceuticals Inc. NC
- Humacyte, Inc. NC
- PROKIDNEY CORP. NC
- Pelthos Therapeutics Inc. NC
In other datasets, the same topic (Health) in NC:
- Nonprofit: 24 FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health